Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-IBD: MT-501 and MT-201 for Crohn's Disease and Ulcerative Colitis
NCT07113522Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of MT-501, MT-201 in Crohn's disease, ulcerative colitis (UC). Started Jun 2025; status: recruiting.
02
Drugs
MT-501MT-201
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07113522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113522.